EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Purification processes of live virus vaccine candidates expressed in adherent Vero cell lines via multimodal chromatography in flowthrough mode

Spyridon Konstantinidis, Murphy R Poplyk, Wanli Justin Ma, Devan Reilly, Young Zhang, Jamin Wang, Rachel Thompson, Alyssa Stiving, Michael A Winters, Sheng-Ching Wang, Adam Kristopeit

Biotechnology and Bioengineering · 2024

DOI: 10.1002/bit.28430 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2024. Written by Spyridon Konstantinidis and 10 co-authors. Institution: Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA. Major MEDLINE topics: Ultrafiltration. Cited 10 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Live virus vaccine (LVV) purification, employing chromatography, can be challenged by low binding capacities and elution yields. Alternatively, processes relying solely on enzymatic digestion steps and size‐based membrane separations can be limited by suboptimal reduction of process related impurities and poorly scalable unit operations. Here, we demonstrate that the combination of flowthrough mode chromatography and an ultrafiltration/diafiltration (UF/DF) unit operation delivers a purification process for two different LVV candidates, V590 and Measles, expressed in adherent Vero cells. For V590, chromatography with mixed mode cation exchange resins returned final product yields of ∼50% and logarithmic reduction values (LRVs) of 1.7–>3.4 and 2.5–3.0 for host cell DNA (hcDNA) and host cell proteins (HCPs), respectively. For Measles, chromatography with mixed mode anion exchange resins returned final product yields of ∼50% and LRVs of 1.6 and 2.2 for hcDNA and HCPs, respectively. For both V590 and Measles processing, the employed resins cleared a key HCP, fibronectin, which could foul the UF/DF unit operation, and thusly enabling it to further reduce HCPs and to formulate the final LVV products. This integrated purification process utilizes the complementary action of the two unit operations and its applicability across LVVs supports its consideration for their processing.

Subjects

MeSH terms (MEDLINE)

UltrafiltrationAnimalsChlorocebus aethiopsVero CellsVaccines, AttenuatedViral VaccinesChromatography, Ion Exchange

Author keywords

chromatographydownstream processhigh throughputlive virus vaccine

Substances

Vaccines, AttenuatedViral Vaccines

Authors and institutions

  • Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.

Cite

APA

Konstantinidis, S., Poplyk, M. R., Ma, W. J., Reilly, D., Zhang, Y., Wang, J., Thompson, R., Stiving, A., Winters, M. A., Wang, S. C., & Kristopeit, A. (2024). Purification processes of live virus vaccine candidates expressed in adherent Vero cell lines via multimodal chromatography in flowthrough mode. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28430

Vancouver

Konstantinidis S, Poplyk MR, Ma WJ, Reilly D, Zhang Y, Wang J, et al. Purification processes of live virus vaccine candidates expressed in adherent Vero cell lines via multimodal chromatography in flowthrough mode. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28430

BibTeX
@article{Konstantinidis2024,
  author = {Konstantinidis, Spyridon and Poplyk, Murphy R and Ma, Wanli Justin and Reilly, Devan and Zhang, Young and Wang, Jamin and Thompson, Rachel and Stiving, Alyssa and Winters, Michael A and Wang, Sheng-Ching and Kristopeit, Adam},
  title = {Purification processes of live virus vaccine candidates expressed in adherent Vero cell lines via multimodal chromatography in flowthrough mode},
  journal = {Biotechnology and Bioengineering},
  year = {2024},
  doi = {10.1002/bit.28430}
}
Start for free →